We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.
Adherence Measurement and Incidence of Bleeding and Systemic Embolism with Dabigatran in a Medicaid Population
Authors
Trask, NicoleKotadiya, Payal N.
Gagnon, James
Kohn, Mark
Lavitas, Pavel
Lee, Karen
Lewtas, Andrea
Lowe, Maria M.
Nacopoulos, Alkiviadis
Rosenzweig, Tamara
Alper, Caroline
Jeffrey, Paul
Document Type
Poster AbstractPublication Date
2013-05-08Keywords
CardiologyCardiovascular Diseases
Pharmacy and Pharmaceutical Sciences
Therapeutics
Translational Medical Research
Metadata
Show full item recordAbstract
BACKGROUND: The use of warfarin for the treatment of atrial fibrillation (AF) is often complicated by the associated narrow therapeutic index and frequent monitoring. Dabigatran, an oral direct thrombin inhibitor, does not require routine monitoring, produces rapid therapeutic anticoagulation, and has the potential to improve thromboprophylaxis through increased adherence. As such, it is important to evaluate adherence and the incidence of bleeding and systemic embolism with dabigatran in a real-world population with AF. OBJECTIVE: To measure adherence and incidence of bleeding and systemic embolism with dabigatran in a state Medicaid population with AF. METHODS: Medicaid members >18 years of age with AF were included if they had >1 paid claim for dabigatran between February 1, 2011 and September 30, 2011. Members were excluded if they had breaks in Medicaid coverage, supplemental insurance or were a female of childbearing age. The index date was defined as the date of the first pharmacy claim for dabigatran. Adherence was measured using medication possession ratios (MPR) for members with >2 paid claims for dabigatran and members with an MPR >0.8 were considered adherent. The incidences of bleeding, stroke and all-cause hospitalization were determined using medical claims data for one year post-index date. Pharmacy claims data was used to report changes in anticoagulant therapy within one year post-index date. RESULTS: The average MPR was 0.87 and 69% of members were considered adherent. Of the members that started dabigatran, 42.9% continued dabigatran while 21.4% switched to warfarin. Overall, 16.7% of members experienced a systemic embolism and only one bleeding event occurred during the study period. While chest pain and dyspepsia were the most common adverse events, 45.2% of members had no adverse events. CONCLUSIONS: This evaluation found that while members were adherent to dabigatran therapy, the discontinuation rate suggests poor tolerance to therapy.DOI
10.13028/q5pd-c986Permanent Link to this Item
http://hdl.handle.net/20.500.14038/27831Rights
Copyright the Author(s)Distribution License
http://creativecommons.org/licenses/by-nc-sa/3.0/ae974a485f413a2113503eed53cd6c53
10.13028/q5pd-c986